An Innovative antibody-based Plug-and-Play strategy for SARS-CoV-2
Tushir-Singh, J.; Shivange, G. N.; Gogoi, D.
Show abstract
The novel and highly pathogenic coronavirus (SARS-CoV-2) remains a public health threat worldwide. SARS-CoV-2 enters human host lung cells via its spike protein binding to angiotensin-converting enzyme 2 (ACE2) in a process critical dependent on host protease-mediated fusion event. Thus, effective targeted therapies blocking the first step of viral fusion and cellular entry remains a critical unmet medical need to overcome disease pathology. Here we engineered and describe an antibody-based novel and targeted plug-and-play strategy, which directly competes with the proteolytic activation function of SAR-CoV-2 spike protein. The described strategy involves the engineering of furin substrate residues in IgG1 Fc-extended flexible region of spike targeting antibody. Our results with spike receptor-binding domain (RBD) targeting CR3022 antibody support blockade of the viral function using proof of concept ACE2 overexpressing cells. Our study reveals analytical, safe, and selective mechanistic insights for SARS-CoV-2 therapeutic design and is broadly applicable to the future coronaviridae family members (including mutant variants) exploiting the host protease system for cellular entry.
Matching journals
The top 11 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- OST Catalytic Subunit Redundancy Enables Therapeutic Targeting of N-Glycosylation 93%
- VIPER-TACs leverage viral E3 ligases for disease-specific targeted protein degradation 93%
- Engineering ERα degraders with pleiotropic ubiquitin ligase ligands maximizes therapeutic efficacy by co-opting distinct effector ligases 92%
Similar papers in this journal
- Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses 92%
- Broad SARS-CoV-2 Neutralization by Monoclonal and Bispecific Antibodies Derived from a Gamma-infected Individual 92%
- Recognition determinants of improved HIV-1 neutralization by a heavy chain matured pediatric antibody 91%
Similar papers in this journal
- Peptide-antibody Fusions Engineered by Phage Display Exhibit Ultrapotent and Broad Neutralization of SARS-CoV-2 Variants 92%
- Designer small molecule control system based on Minocycline induced disruption of protein-protein interaction. 92%
- A Nimbolide-Based Kinase Degrader Preferentially Degrades Oncogenic BCR-ABL 91%
Similar papers in this journal
Similar papers in this journal
- DMBT1 promotes SARS-CoV-2 infection and its SRCR-derived peptide inhibits SARS-CoV-2 infection 90%
- Cellular electrical impedance to profile SARS-CoV-2 fusion inhibitors and to assess the fusogenic potential of spike mutants 90%
- SARS-CoV-2 Permissive Glioblastoma Cell Line for High Throughput Antiviral Screening 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.